Patents by Inventor John J. Siekierka

John J. Siekierka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
    Patent number: 8986696
    Abstract: The present invention relates to trans-capsularly administering into a diseased joint an inhibitor of p38 MAP kinase or a different therapeutic agent.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: March 24, 2015
    Assignee: DePuy Mitek, Inc.
    Inventors: Laura J. Brown, Jeffery C. Geesin, Carrie H. Fang, John J. Siekierka
  • Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
    Publication number: 20090162376
    Abstract: The present invention relates to trans-capsularly administering into a diseased joint an inhibitor of p38 MAP kinase or a different therapeutic agent.
    Type: Application
    Filed: December 21, 2007
    Publication date: June 25, 2009
    Inventors: Laura J. Brown, Jeffery C. Geesin, Carrie H. Fang, John J. Siekierka
  • Transdiscal administration of inhibitors of p38 MAP kinase
    Publication number: 20090162351
    Abstract: The present invention relates to methods, formulations and kits for administering a p38 MAP kinase inhibitor or other therapeutic agent into an intervertebral disc, such as a diseased disc, for example, for purposes of prevention and treatment of degenerative and other disorders.
    Type: Application
    Filed: December 21, 2007
    Publication date: June 25, 2009
    Applicant: DePuy Spine, Inc.
    Inventors: Laura J. Brown, Jeffery C. Geesin, Carrie H. Fang, John J. Siekierka
  • IRAK modified transgenic animals
    Patent number: 6166289
    Abstract: A transgenic animal with alterations in an IRAK gene is prepared by introduction of an altered IRAK gene into a host animal. The resulting transgenic animals do not produce functional IRAK molecules. Cells and cell lines derived from these animals also contain the altered IRAK gene.
    Type: Grant
    Filed: May 13, 1999
    Date of Patent: December 26, 2000
    Assignee: Ortho-McNeil Pharmacueticals
    Inventors: Crafford A. Harris, John J. Siekierka, Per A. Peterson, Wai-Ping Leung
  • Recombinant human thymopoietin proteins and uses therefor
    Patent number: 5472856
    Abstract: The present invention provides novel nucleotide and amino acid sequences for human thymopoietin .alpha., .beta., and .gamma., methods of recombinantly expressing same, and diagnostic and therapeutic uses thereof.
    Type: Grant
    Filed: December 21, 1993
    Date of Patent: December 5, 1995
    Assignee: Immunobiology Research Institute, Inc.
    Inventors: Crafford A. Harris, Gideon Goldstein, John J. Siekierka, Mary A. Talle, Ponniah Shenbagamurthi, Michael D. Culler, Diane R. Setcavage
  • New FK-506 cytosolic binding protein
    Patent number: 5196352
    Abstract: A new homogeneous cytosolic binding (HCB) protein, having a specific binding activity of about 26 .mu.g FK-506 per mg protein and a molecular weight of about 10-12 kilodaltons, reversibly binds the immunosuppressant FK-506 but not cyclosporine A (CSA). The protein is stable to heating at 56 degrees C. for 30 minutes retaining its FK-506 binding affinity, and has the (partial) amino terminal amino acid sequence: H.sub.2 N G y V l G n V l G u T r I e S r P o G y A p G y A g T r P e P o L s A g-Gly-Gln-Thr-X-Val-Val-Val-His-Tyr-Thr-Gly-Met-Leu-Glu-Asp-Fly-Lys-Phe-AS p (wherein X is undefined). The HCBV protein is isolated from the cytosol of mammalian tissues, preferably human neoplastic T-cell lines, e.g. Jurkat, and can be used in diagnostic and purification procedures involving FK-506 macrolide type immunosuppressants. The HCB protein also catalyses the cis-trans isomerization of proline-containing peptide bonds.
    Type: Grant
    Filed: June 27, 1991
    Date of Patent: March 23, 1993
    Assignee: Merck & Co., Inc.
    Inventors: John J. Siekierka, Hsuen-Yun Hung, Marie J. Staruch, Nolan H. Sigal, Richard A. Mumford
  • FK-506 cytosolic binding protein
    Patent number: 5109112
    Abstract: A new homogeneous cytosolic binding (HCB) protein, having a specific binding activity of about 26 .mu.g FK-506 per mg protein and a molecular weight of about 10-12 kilodaltons, reversibly binds the immunosuppressant FK-506 but not cyclosporine A (CSA). The protein is stable to heating at 56 degrees C. for 30 minutes retaining its FK-506 binding affinity, and has the (partial) amino terminal amino acid sequence: H.sub.2 N-Gly-Val-Gln-Val-Glu-Thr-Ile-Ser-Pro- Gly-Asp-Gly-Arg-Thr-Phe-Pro-Lys- Ar g-Gly-Gln-Thr-X-Val-Val-His-Tyr-Thr-Gly-Met-Leu-Glu-Asp-Gly-Lys-Lys-Phe-As p (wherein X is undefined). The HCB protein is isolated from the cytosol of mammalian tissues, preferably human neoplastic T-cell lines, e.g., Jurkat, and can be used in diagnostic and purification procedures involving FK-506 macrolide type immunosuppressants. The HCB protein also catalyzes the cis-trans isomerization of proline-containing peptide bonds.
    Type: Grant
    Filed: July 5, 1990
    Date of Patent: April 28, 1992
    Assignee: Merck & Co., Inc.
    Inventors: John J. Siekierka, Hsuen-Yun Hung, Marie J. Staruch, Nolan H. Sigal, Richard A. Mumford